WSC 2025 | Next steps in the research of Factor XIa inhibition for secondary stroke prevention
Mike Sharma, MD, MSc, FRCPC, McMaster University, Hamilton, Canada, discusses the next steps in the research of Factor XIa inhibition for secondary stroke prevention. He highlights the ongoing OCEANIC-STROKE (NCT05686070) and LIBREXIA-STROK (NCT05702034) trials, stating that the results of these trials will be the starting point for further research. This interview took place at the 17th World Stroke Congress (WSC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, you know, OCEANIC-STROKE is due to complete. LIBREXIA-STROK, which is a large phase three trial in stroke patients using milvexian, will complete later. We don’t yet know the exact timeline for completion of that trial. There is as well a trial in atrial fibrillation aimed at stroke prevention using milvexian as well. I think once we have the data, no matter what the magnitude or direction of the effect, it will be the beginning, really, of research into this area...
So, you know, OCEANIC-STROKE is due to complete. LIBREXIA-STROK, which is a large phase three trial in stroke patients using milvexian, will complete later. We don’t yet know the exact timeline for completion of that trial. There is as well a trial in atrial fibrillation aimed at stroke prevention using milvexian as well. I think once we have the data, no matter what the magnitude or direction of the effect, it will be the beginning, really, of research into this area. So far, the trial’s been proceeding well. We’ve not had a signal of a safety concern from the DSMB. So really, this is going to be something that hinges on efficacy. Things look very safe at present. And I think what we’re going to need to study further is what stroke subtypes, what characteristics of the patient optimize the response to this. What we need to do further in terms of discovering modifications on this or modifications in the treatment would lead to even better efficacy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
